Bandaru Sai Samyuktha, Multani Naveen Singh, Nauam William Thomas, Benitez-Farina Cibar
Hematology Oncology Department, Ascension Providence Hospital/Michigan State University College of Human Medicine, Southfield, MI, USA.
Internal Medicine Department, Ascension Providence Hospital/Michigan State University College of Human Medicine, Southfield, MI, USA.
Case Rep Oncol. 2024 Sep 23;17(1):1063-1069. doi: 10.1159/000540979. eCollection 2024 Jan-Dec.
Multiple myeloma represents a malignant disorder of plasma cells. Extramedullary relapse in multiple myeloma is a rare occurrence, and pericardial involvement stands as an exceedingly uncommon manifestation. Only a few documented cases of pericardial effusion as an extramedullary relapse presentation of myeloma exist. Bispecific antibodies are emerging as a novel class of immunotherapy drugs for the treatment of relapsed refractory multiple myeloma patients who have experienced failure with four prior lines of therapy. According to a literature review, none of the reported cases with pericardial effusion relapsed myeloma have been treated with bispecific antibodies, given that these drugs have only recently gained approval.
We present a rare case of a patient with pericardial effusion resulting from myeloma relapse, treated with teclistamab, a bispecific antibody, and achieving an excellent response.
Bispecific antibodies, such as teclistamab, show great effectiveness as a treatment for patients with relapsed refractory multiple myeloma, including those with extramedullary disease.
多发性骨髓瘤是一种浆细胞恶性疾病。多发性骨髓瘤的髓外复发很少见，心包受累是一种极为罕见的表现。仅有少数关于心包积液作为骨髓瘤髓外复发表现的病例记载。双特异性抗体作为一类新型免疫治疗药物正在兴起，用于治疗先前接受过四线治疗均失败的复发难治性多发性骨髓瘤患者。根据文献综述，鉴于这些药物最近才获批，尚无报道的骨髓瘤心包积液复发病例接受过双特异性抗体治疗。
我们报告一例罕见病例，一名因骨髓瘤复发导致心包积液的患者，接受双特异性抗体替雷利珠单抗治疗，并取得了极佳疗效。
双特异性抗体，如替雷利珠单抗，对复发难治性多发性骨髓瘤患者，包括伴有髓外疾病的患者，显示出巨大的治疗效果。
